Cargando…
Effect of (1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients
We previously reported the results of a phase II trial of anti‐PD‐1 antibody plus anti‐vascular endothelial growth factor receptor 2 inhibitors and eribulin in heavily pretreated advanced triple‐negative breast cancer with a favorable objective response rate (ORR) of 37.0% (NCT04303741). Here we rep...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551590/ https://www.ncbi.nlm.nih.gov/pubmed/37640025 http://dx.doi.org/10.1111/cas.15937 |
_version_ | 1785115801801457664 |
---|---|
author | Tian, Zhenluan Rao, Qunxian He, Zhanghai Zhao, Wei Chen, Liangyu Liu, Jieqiong Wang, Ying |
author_facet | Tian, Zhenluan Rao, Qunxian He, Zhanghai Zhao, Wei Chen, Liangyu Liu, Jieqiong Wang, Ying |
author_sort | Tian, Zhenluan |
collection | PubMed |
description | We previously reported the results of a phase II trial of anti‐PD‐1 antibody plus anti‐vascular endothelial growth factor receptor 2 inhibitors and eribulin in heavily pretreated advanced triple‐negative breast cancer with a favorable objective response rate (ORR) of 37.0% (NCT04303741). Here we report updated survival outcomes and serum metabolite changes of the study. Proton nuclear magnetic resonance spectroscopy was used to detect metabolite dynamics and explore biomarkers for response. We found that treatment‐sensitive patients had higher very low‐density lipoprotein‐related metabolite expression at baseline. A lipid proteomics model consisting of six metabolites predicted ORR and progression‐free survival at 6 months with area under the receiver operating characteristic curves of 0.88 and 0.87, respectively. Serum asparagine and sarcosine concentrations were significantly higher after treatment in treatment‐resistant patients. In conclusion, we constructed a model consisting of six metabolites to identify patients who benefit more from the triplet treatment, and asparagine and sarcosine may be associated with treatment resistance. |
format | Online Article Text |
id | pubmed-10551590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105515902023-10-06 Effect of (1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients Tian, Zhenluan Rao, Qunxian He, Zhanghai Zhao, Wei Chen, Liangyu Liu, Jieqiong Wang, Ying Cancer Sci Original Articles We previously reported the results of a phase II trial of anti‐PD‐1 antibody plus anti‐vascular endothelial growth factor receptor 2 inhibitors and eribulin in heavily pretreated advanced triple‐negative breast cancer with a favorable objective response rate (ORR) of 37.0% (NCT04303741). Here we report updated survival outcomes and serum metabolite changes of the study. Proton nuclear magnetic resonance spectroscopy was used to detect metabolite dynamics and explore biomarkers for response. We found that treatment‐sensitive patients had higher very low‐density lipoprotein‐related metabolite expression at baseline. A lipid proteomics model consisting of six metabolites predicted ORR and progression‐free survival at 6 months with area under the receiver operating characteristic curves of 0.88 and 0.87, respectively. Serum asparagine and sarcosine concentrations were significantly higher after treatment in treatment‐resistant patients. In conclusion, we constructed a model consisting of six metabolites to identify patients who benefit more from the triplet treatment, and asparagine and sarcosine may be associated with treatment resistance. John Wiley and Sons Inc. 2023-08-28 /pmc/articles/PMC10551590/ /pubmed/37640025 http://dx.doi.org/10.1111/cas.15937 Text en © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Tian, Zhenluan Rao, Qunxian He, Zhanghai Zhao, Wei Chen, Liangyu Liu, Jieqiong Wang, Ying Effect of (1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
title | Effect of
(1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
title_full | Effect of
(1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
title_fullStr | Effect of
(1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
title_full_unstemmed | Effect of
(1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
title_short | Effect of
(1)H‐NMR serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
title_sort | effect of
(1)h‐nmr serum lipoproteins on immunotherapy response in advanced triple‐negative breast cancer patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551590/ https://www.ncbi.nlm.nih.gov/pubmed/37640025 http://dx.doi.org/10.1111/cas.15937 |
work_keys_str_mv | AT tianzhenluan effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients AT raoqunxian effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients AT hezhanghai effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients AT zhaowei effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients AT chenliangyu effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients AT liujieqiong effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients AT wangying effectof1hnmrserumlipoproteinsonimmunotherapyresponseinadvancedtriplenegativebreastcancerpatients |